Last reviewed · How we verify
VPM1002 live vaccine
At a glance
| Generic name | VPM1002 live vaccine |
|---|---|
| Sponsor | Serum Life Science Europe GmbH |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa (PHASE1, PHASE2)
- Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence (PHASE2, PHASE3)
- Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and Severity (PHASE3)
- Study to Evaluate the Safety and Immunogenicity of VPM1002 in Comparison With BCG in HIV-exposed/-Unexposed Newborn Infants in South Africa (PHASE2)
- Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Newborn Infants in South Africa (PHASE2)
- Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison to BCG in Healthy Volunteers in South Africa (PHASE1)
- Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Male Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VPM1002 live vaccine CI brief — competitive landscape report
- VPM1002 live vaccine updates RSS · CI watch RSS
- Serum Life Science Europe GmbH portfolio CI